Effect of Basis™ and High Intensity Interval Training (HIIT) on Muscle Metabolism and Exercise Performance
NCT ID: NCT04050358
Last Updated: 2023-02-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
PHASE1
INTERVENTIONAL
2023-02-28
2023-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The study will consist of a screening visit, baseline visit, followed by treatment and HIIT phase (3 weeks) and a post-supplementation, follow-up visit (this will occur 48 h (or more) after the final HIIT session). Following the screening phase, subjects who meet entry criteria will be randomly assigned to 1 of 2 treatment groups: recommended dose of BasisTM (250 mg Nicotinamide Riboside and 50 mg Pterostilbene) per day or matching-placebo in a 1:1 ratio.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Beta-alanine Supplementation and High-intensity Interval Training
NCT03708185
The Effect of β-hydroxy-β-methylbutyrate Supplementation on Physical Capacity and Body Composition in Trained Athletes
NCT03028649
The Effects of 10 Days of Extreme Endurance on Performance
NCT03337737
Chronic Study on Body Composition, Training, Performance, and Recovery
NCT04230824
Effects of 14-days of HMB-free Acid on Changes in Muscle During 4-days of Survival Training
NCT02503007
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
OTHER
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1X dose of NRPT
NRPT
Subjects randomly assigned to the active group will receive Nicotinamide Riboside and Pterostilbene (each capsule contains 125 mg NR and 25 mg PT, total daily dose is 2 capsules) for 3 weeks
Placebo
Placebo oral capsule
Subjects randomly assigned to the Placebo group will receive placebo oral capsules for 3 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
NRPT
Subjects randomly assigned to the active group will receive Nicotinamide Riboside and Pterostilbene (each capsule contains 125 mg NR and 25 mg PT, total daily dose is 2 capsules) for 3 weeks
Placebo oral capsule
Subjects randomly assigned to the Placebo group will receive placebo oral capsules for 3 weeks
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Body mass index between 18.5-30 kg.m-2
* Ability to give informed consent
* Recreationally active (defined in the present study as exercising once a week or more).
Exclusion Criteria
* Currently taking supplements known to affect metabolism (e.g. ibuprofen, stimulants, vitamins, NR)
* Taking prescribed medication
* Consuming a vegan diet
* Consuming a high fat, low carbohydrate diet
* Habitual consumption of protein and/or dairy supplements (e.g. whey protein)
* Smokers
18 Years
35 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Exeter
OTHER
Elysium Health
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Timothy Etheridge, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Exeter
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Exeter
Exeter, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Basis-HIIT
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.